Trial Profile
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Administered in Korean Patients According to the Prescribing Information
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Acronyms BONPMS
- Sponsors GlaxoSmithKline
- 29 Jun 2011 New trial record